How Biopharma & Medical Device Companies are Pivoting to Support the Boom in Telehealth During the COVID-19 Pandemic and Beyond

Non-members: Click here to review a complimentary excerpt from “How Biopharma & Medical Device Companies are Pivoting to Support the Boom in Telehealth During the COVID-19 Pandemic and Beyond”

Telehealth paves the way for convenient, affordable and readily-accessible health services in even the remotest areas. These features have accelerated the use of telehealthcare during the COVID-19 outbreak, causing many biopharma and medical device organizations to pivot find ways to support these rapidly emerging telehealth channels.

However, biopharma manufacturers are struggling to develop coherent strategies, identify logical approaches and adopt novel tools to ensure that they can provide valuable telehealth support services for physicians and patients.

Best Practices, LLC undertook this benchmarking research to understand how biopharmaceutical and medical device companies have pivoted to support a world where telemedicine is emerging as a permanent healthcare delivery channel.

This research provides benchmarks around the impact of operational services delivered via telehealth channels, valuable telehealth services offered by various biopharma groups, key lessons learned in each operational / functional area during COVID-19, and telehealth change duration.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Medical Device; Health Care; Biotech; Consulting; Clinical Research; Laboratories; Medical


Companies Profiled:
AbbVie; Alkermes; Ascensia; AstraZeneca; BioDelivery Sciences International; Inc.; B.Braun; Canopy Growth; Catalyst Pharma; Daiichi Sankyo; DBV Tehcnologies; Dendreon Pharmaceuticals LLC; DiaSorin; EHOB; Inc; eNeura Therapeutics; Frankel Advisory Group LLC; Galderma; Greenwich Biosciences; Johnson & Johnson; Merck; Novartis; Panacea Biotec; Pfizer; Piramal Group; Rigel Pharmaceuticals; Sanofi; Santen; Sivantos Pte. Ltd.; Stgilesmedical London & Berlin; Sumitovant BioPharma; UCB Pharma; ViiV Healthcare; Zydus Cadila

Study Snapshot

Best Practices, LLC engaged 36 leaders from 32 biopharma and medical device organizations in this research through a benchmarking survey. Ninety percent of the participants serve at the director-level and above.

Key topics covered in this research include:

• Impact of Operational Services via Telehealth Channel
• Telehealth Service Channels
• Key Lessons Learned
• Telehealth Change Duration

Key Findings

Select key insights uncovered from this research are noted below. Detailed findings are available in the full study.

• Telehealth channel attraction will continue its growth across all operational areas post COVID-19 pandemic: Patient Support and Medical Affairs will have prominent roles in patient education and clinical support, whereas Sales will be the first to try and offer services via telehealth channel. Health Outcomes plans to offer valuable tele-services in the clinical support space.

• Pharma plans to evolve delivery of outcomes studies (88%), support aids (76%), education & program support for providers and patients (>60%) over the telehealth channel. Currently, 60% of industry sales leaders provide targeted support through the tele-channel.

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.